Namouni to lead Blueprint R&D; plus Davar to head R&D at Acadia, Napolitano replaces Burow on Vir’s board, and more
Precision cancer therapy play Blueprint Medicines Corp. (NASDAQ:BPMC) hired Fouad Namouni as president of R&D to head an R&D organization within which CSO Marion Dorsch and CMO Andy Boral will continue to lead research and clinical development functions, respectively. Namouni joined Blueprint from Bristol Myers Squibb Co. (NYSE:BMY), where he has held leadership positions since 1999, departing in April as SVP and head of oncology development. His track record includes checkpoint inhibitors Opdivo nivolumab and Yervoy ipilimumab.
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) hired Gudarz Davar as EVP and head of R&D. President Serge Stankovic will continue to oversee the CNS disorders company’s R&D, regulatory, medical affairs, external innovation and pharmacovigilance functions. Davar was VP and head of global neurology clinical development at Eli Lilly and Co. (NYSE:LLY)...